New drug targets tough cancers with KRAS G12V mutation
NCT ID NCT06715124
First seen Mar 04, 2026 · Last updated Apr 29, 2026 · Updated 7 times
Summary
This early-phase study tests a new drug, QTX3544, in people with advanced solid tumors that have a specific genetic mutation called KRAS G12V. The main goals are to check the drug's safety and how well it works, either alone or with another drug called cetuximab. About 237 participants will be enrolled to help find the right dose and see if the drug can shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Duke Cancer Center
Durham, North Carolina, 27705, United States
-
Florida Cancer Specialists & Research Institute
Sarasota, Florida, 34232, United States
-
Huntsman Cancer Institute, University of Utah
Salt Lake City, Utah, 84112, United States
-
Sarah Cannon Research Institute
Denver, Colorado, 80218, United States
-
Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States
-
South Texas Accelerated Research Therapeutics Mountain Region, LLC
West Valley City, Utah, 84119, United States
-
South Texas Accelerated Research Therapeutics, LLC Midwest
Grand Rapids, Michigan, 49546, United States
-
South Texas Accelerated Research Therapeutics, LLC San Antonio
San Antonio, Texas, 78229, United States
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Yale Cancer Center
New Haven, Connecticut, 06511, United States
Conditions
Explore the condition pages connected to this study.